-
BG Medicine; ACS Biomarker; Cardiovascular Research Institute Maastricht; Medrad; Bayer HealthCare; Possis Medical; Merit Medical Systems; Micrus Endovascular; Mindray Medical International; Datascope; Nfocus Neuromedical; Acta Vascular Systems
-
InspireMD (Tel Aviv, Israel) reported that it has launched the MGuard Coronary Stent in Italy. MGuard received CE-mark approval in October to treat patients with coronary artery diseases. Distribution of MGuard in Italy will be carried out by InspireMD's Italian distributor, Kardia (Milan).
-
Stroke, besides being the third leading cause of death in the U.S., also can claim an impressive number of stroke drugs. Clinical trial failures number in the dozens. And preventive possibilities remain about equally slim.
-
A commonly used medication that prevents blood clots from forming may also prevent existing clots from damaging delicate vein walls and may accelerate healing in a clot-damaged area of vein wall, according to new research from the University of Michigan (U-M) Cardiovascular Center (Ann Arbor, Michigan).
-
As if we didn't already have enough privacy and security concerns to worry about, the medical device industry must add one more to the "not absolutely secure" list. A team of researchers has demonstrated that devices monitored by telemetry can be disrupted wirelessly thus, essentially hackable.
-
NEW ORLEANS As balmy spring days bathed "The Big Easy" last month during the 33rd annual International Stroke Conference, sponsored by the American Stroke Association (ASA; Dallas), one could not help but think of the saying "hope springs eternal" even concerning one of the most troubling of all healthcare issues.
-
In this large, multi-site randomized clinical trial in older patients with non-Hodgkin lymphoma (NHL), R-CHOP-14 proved superior to CHOP-14 and 8 cycles offered no advantage compared with 6.
-
In a series of patients with metastatic breast cancer peripheral blood and bone marrow were assayed for the detection of breast cancer cells. Breast cancer cells were found in the bone marrow in 59% of patients but their presence did not provide prognostic information with regard to survival. In contrast, survival was significantly worse for the 41% of patients with detectable circulating breast cancer cells.
-
In a prospective randomized trial comparing post-surgical follow-up for patients with Stage III and IV colon cancer, PET-CT was found to detect recurrence earlier and to result in a greater number of patients eligible for surgical resection of isolated metastases when compared to conventional follow-up schedules that include CT scanning.
-
